Catalyst Wire Dossier Catalyst Wire Dossier

HHT

hypomethylating agent (unspecified)
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HHT, covering 2021-04-01 to 2021-04-01. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy [Phase 2]

See pricing